Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Bellerophon Therapeutics, Inc. (BLPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/15/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 04/06/2020 |
8-K
| Quarterly results|
Docs:
|
"Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results WARREN, N.J., April 6, 2020 - Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019. “We are extremely pleased with the significant progress achieved with our clinical program for INOpulse® to address multiple unmet cardiopulmonary diseases. Most notably, we reported positive top-line results from Phase 2 of our ongoing Phase 2/3 clinical study of INOpulse for the treatment of PH-PF, completed our End-of-Phase 2 meetings with the U.S. Food and Drug Administration , and reache..." |
|
| 11/06/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results WARREN, N.J., May 9, 2019 -- Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2019. “Bellerophon has achieved substantial progress in the beginning of 2019 with additional important milestones expected later this year,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “We reported positive results from Cohort 1 of our ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study of INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease . The study demonstrated a clinically and statistically significant improvement ..." |
|
| 11/07/2018 |
8-K
| Quarterly results|
Docs:
|
"Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results WARREN, N.J., November 7, 2018 -- Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2018. “We are pleased to have completed enrollment in the first cohort of our inhaled nitric oxide for pulmonary fibrosis Phase 2b study in pulmonary hypertension associated with interstitial lung disease , and look forward to the results, which are expected in January 2019,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “The additional cohorts are expected to begin enrolling later this year, with results anticipated in 2019. The additional cohorts will allow us to assess highe..." |
|
| 08/01/2018 |
8-K
| Quarterly results |
| 05/10/2018 |
8-K
| Quarterly results |
| 03/15/2018 |
8-K
| Quarterly results |
| 11/07/2017 |
8-K
| Quarterly results |
| 08/07/2017 |
8-K
| Quarterly results |
| 05/15/2017 |
8-K
| Form 8-K - Current report |
| 03/13/2017 |
8-K
| Form 8-K - Current report |
| 11/08/2016 |
8-K
| Form 8-K - Current report |
| 08/09/2016 |
8-K
| Form 8-K - Current report |
| 05/21/2015 |
8-K
| Quarterly results |
|
|